Lexicon Pharmaceuticals Inc LXRX:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/18/22 EDT
1.64quote price arrow down-0.10 (-5.75%)
Volume
373,504
52 week range
1.60 - 6.33
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.64
  • 52 Week High6.33
  • 52 Week High Date10/15/21
  • 52 Week Low1.60
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap245.33M
  • Shares Out149.59M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.53
  • YTD % Change-58.38

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.64
  • 52 Week High6.33
  • 52 Week High Date10/15/21
  • 52 Week Low1.60
  • 52 Week Low Date05/11/22
  • Market Cap245.33M
  • Shares Out149.59M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.53
  • YTD % Change-58.38

RATIOS/PROFITABILITY

  • EPS (TTM)-0.61
  • P/E (TTM)-2.68
  • Fwd P/E (NTM)-2.60
  • EBITDA (TTM)-89.267M
  • ROE (TTM)-73.62%
  • Revenue (TTM)310,000.00
  • Gross Margin (TTM)87.99%
  • Net Margin (TTM)-29,310.39%
  • Debt To Equity (MRQ)25.33%

EVENTS

  • Earnings Date07/28/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lexicon Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an...
Raymond Debbane
Independent Chairman of the Board
Lonnel Coats
Chief Executive Officer, Director
Jeffrey Wade
President, Chief Financial Officer
Alan Main Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Wendy Mcdermott
Vice President - Human Resources
Kristen Alexander
Vice President - Finance and Accounting
Address
2445 TECHNOLOGY FOREST BLVD., SUITE 1100
The Woodlands, TX
77381
United States

Top Peers

SYMBOLLASTCHG%CHG
TALS
Talaris Therapeutics Inc
7.60-1.29-14.51%
MRSN
Mersana Therapeutics Inc
3.29-0.08-2.37%
PRVB
Provention Bio Inc
4.17-0.35-7.74%
ACIU
AC Immune SA
3.20+0.10+3.23%
ALVR
Allovir Inc
4.31-0.29-6.30%